Thus, ANXA1 is upregulated in 5FU-resistant CRC, contributing to treatment resistance both by NF-κB activation and by the promotion of the transcription of survival-related genes, such as XIAP and BCL-2, associated with the concomitant inhibition of pro-apoptotic factors [25]. The gene discussed is NFKB1; the disease is colorectal carcinoma.